DALLAS, Nov. 1, 2021 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, today announced that its proprietary
A.I. platform RADR® has exceeded 10.4 billion
datapoints. RADR® is Lantern's proprietary integrated
A.I. platform for large-scale biomarker and drug-tumor interaction
data analytics that leverages machine-learning. RADR® is
used to provide mechanistic insights about drug-tumor interactions,
predict the potential response of cancer types and subtypes to
existing drugs and drug candidates, and uncover patient groups that
may respond to potential therapies being developed by Lantern and
its collaborators.
RADR® is also being used to: (1) help define and
develop combination strategies involving drugs in development by
Lantern and existing drugs that are approved for a range of
oncology indications; (2) guide the prioritization of potential
indications for development; and (3) identify potential new drug
candidates to in-license and develop.
The increase to 10.4 billion datapoints was also accompanied by
other significant improvements in the functionality, feature set
and further automation of RADR®, which are intended to
help scale the A.I. platform's drug development capabilities. The
significant increase in the number of drug-tumor interaction data
sets and cancers sub-types covered by RADR® includes new
data from collaborations in glioblastoma multiforme (GBM) and
pancreatic cancer and data from transcriptome, genome and methylome
data-sets in blood, bladder and other rare cancers being considered
for future development or have limited therapeutic options.
Panna Sharma, CEO and President
of Lantern Pharma, stated, "Our team has been well ahead of
schedule in the growth of our platform, and RADR® has
now surpassed 10.4 billion data points covering more cancer
sub-types, which further advances our goal of building the most
complete and powerful A.I. platform for precision oncology drug
development. Additionally, the new data will drive insights and
potential drug-candidate innovations faster and into areas of
cancer that have remained untouched or intractable."
Corresponding with this growth in datapoints, the Company has
also focused resources and technology development on the growth and
improvements to the library of algorithms designed specifically to
help solve challenging data and correlation problems for cancer
drug development. By using an ensemble-based approach in applying
the library of algorithms to statistical, correlative and
inferential problems related to drug-tumor interaction,
RADR® can rapidly analyze large amounts of complex data
and predict with high accuracy how both tumors and patients will
respond to drugs and drug candidates. RADR's ability to rapidly
sift through large amounts of curated and complex datasets is key
in predicting the probability of a tumor or a patient group in
responding to a cancer treatment. Additionally, the
RADR® platform evolves as new datasets are added, which
improves and sharpens the insights generated from the algorithms.
Lantern plans on continuing further RADR®
expansion by incorporating and curating additional datasets from
proprietary studies and public data sources and further automating
the evolution of its library of algorithms. Additionally, the
Company will be augmenting the 10.4 billion datapoints with
additional data from immuno-oncology related studies and clinical
trials, including antigen, immune-response and protein data that it
believes will enable a potentially more robust and more powerful
multiomic analysis. "In the next phase of growth for
RADR® our belief is that we can deepen our capabilities
in novel ADC development and also predict combination therapy
approaches using our drug candidates and existing approved
immuno-oncology therapies," stated Mr. Sharma.
"Previously, the task of identifying new cancer therapies has
been costly, risky, and inefficient. Specifically, studying how
existing compounds and therapeutic combinations can affect
different cancer subtypes often took years, whereas our platform
can reduce many key aspects of this process to months. As a result,
we believe our platform changes the industry paradigm in a
meaningful way. We have witnessed first-hand the growing industry
interest in solutions that innovate the development of precision
therapeutics and combination therapies, which we believe will pave
the road to new partnerships. Accordingly, we believe our growing
A.I. platform will be pivotal in uncovering potential new
therapeutic opportunities and developing insights into the creation
of combination-therapy programs, both internally and through
third-party party collaborations to drive long-term shareholder
value."
RADR's highly scalable machine-learning methods are designed to
guide drug development and yield new biological insights, while
also having the potential to increase response rates and improve
outcomes in clinical trials. The robustness and growing number of
datasets powering RADR® is anticipated to continue to
improve machine-learning results, accelerate automation of other
features and aid oncology drug development for Lantern and its
partners with an ultimate focus on benefitting cancer patients.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
eight disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; our research and development efforts
of our internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development
process; our intention to leverage artificial intelligence, machine
learning and genomic data to streamline and transform the pace,
risk and cost of oncology drug discovery and development and to
identify patient populations that would likely respond to a drug
candidate; estimates regarding potential markets and potential
market sizes; sales estimates for our drug candidates and our plans
to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or
in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none
of our product candidates has received FDA marketing approval, and
we may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
CONTACTS:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
Public Relations
Nicholas
Koulermos, Vice President – 5W Public Relations
lantern@5wpr.com
646-843-1812
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharmas-proprietary-ai-platform-for-precision-oncology-drug-development-radr-surpasses-10-billion-datapoints--significantly-enhancing-precision-medicine-capabilities--expanding-potential-for-biopharma-collaboration-301412848.html
SOURCE Lantern Pharma